Member Info for Num4

current, 0.80, up 36.8%

Very Strong start today, up 26.5%, current SP 0.74

0.72 just paid for 1mil, Live P, up 17.1% at time of writing

http://www.sareum.com/download_file/view/192

Yes, I do think Pfizer will license Tyk2. Remember the trial was always starting this year, now I believe COVID will be an added indication, will this work for COVID though, too difficult to call as we need the immune system more than ever for this virus so dual inhibition may be more harmful. We have the preclinical data for other indications and the current strategy is to prioritise them.
The race is still on, NUFC buyout or TYK2 license...

When Tim releases the preclinical data he will be proven correct and Pfizer will license our compound, All IMO of course..
If you really can't see this potential then just keep researching and try and find a negative. Sareum have some golden eggs.

There is also an argument by Robert Plenge who thinks TYK2 on its own is better, I'm sure a lot of new investors won't have seen this;
https://www.google.com/url?sa=t&source=web&rct=j&url=http://www.nimbustx.com/wp-content/uploads/2017/10/BioCentury-Innovations-Nimble-Move-10.5.2017.pdf&ved=2ahUKEwimpN_UkobpAhXyQkEAHVfUBOkQFjABegQIBxAB&usg=AOvVaw1CgUqdpX922rXZ_xtPQw5k

For the long termers like me, our money is firmly on Tim betting on the future of dual inhibition. Only time will tell.

Sareum has a co-development agreement with SRI International (Menlo Park, CA, US), a non-profit scientific research institute, to develop TYK2 inhibitors in autoimmune diseases. SRI, working under a US Department of Defense (DoD) grant, has completed
a preclinical study using Sareum TYK2/JAK1 inhibitors in lupus disease models and the final report from this study is expected to be made public by the DoD in the near future.

From 2019 annual report page7.

Could find the actual grant and read the terms but not that concerned.

https://www.healio.com/rheumatology/psoriatic-arthritis/news/online/%7B3944516f-d757-4f3d-b5c6-6ebbde3edb45%7D/novel-tyk2-inhibitor-may-be-a-game-changer-for-psoriasis

You got to believe if he thinks this is such a game changer then he will know about all the TYK2s in development.

Demark your perfect example Andy of jumping a negative subject...causing discussion and keeping it in the BB. As if by magic they appear

Nothing to worry about here, we all know the positives here, watch the fools arrive today, mpl back yet..

A placing after Tim has been pushing the COVID link is not his style - he's not your normal AIM CEO.

That's the strongest I've seen it for 8 year, even chk1 deal wasn't this good

As mentioned earlier, our CEO, not a LSE poster is showing us the links to our compounds and COVID-19. Is this out of character for Tim, never have they tweeted so much? It is certainly not like to Tim to try and drive the SP forward, we have been increasingly frustrated by the lack of Sareums ability to link the research they are involved with officially, yet now they are cross referencing work they are not "currently" involved in. Strange actions indeed by the BOD but very welcome.

I think what you should remember is none of this increase has been driven by posters on a BB, it's publications of science within the industry, people read that, see Sareum as a buy and invest. It has been helped by Tim using Twitter to show us the links to COVID, not a poster, the CEO. Us investors then take confidence from that and buy again. Nice bash attempt though, waste of your time.

https://www.proactiveinvestors.co.uk/companies/news/211924/sareum-holdings-shares-soar-as-hybridan-spotlights-read-across-from-big-us-pharma-takeover-deal-211924.html

Another nice read for our tyk2s, big names and little ole Sareum working away in the background on a best in class..

https://www.evaluate.com/vantage/articles/news/trial-results/pfizer-bulls-go-search-hidden-gems

Great Andy, thanks for sharing that.
As we know there is not a one drug cure to this pandemic and Sareums best in class should be licensed to a major as a forward planning strategy, If Pfizer find tofa is having a positive effect then surely they will already want the best in class to go head to head with their own.
Tim has always been a best in class and not first in class strategist, looks like it will prove beneficial. The biggest value driver will be the revenue share of sales, normally we would be talking 4years maybe, this could be 12month maximum..

I think the key event here was Pfizer starting a trial on tofa, and we all know about tofa and how it compares to Sareums offering.

10p zoom party...hahaha